Video

Phase 3 Trial of Ibalizumab ART Therapy Reports Positive Results

Author(s):

"Even though we have a lot of drugs, because of the resistance profile of their virus, they don't have a lot of options, so what these results mean for the most vulnerable of our patients is that they have access now to a new class of drugs," Emu concluded.

At CROI 2917, Brinda Emu, MD, assistant professor of Medicine, Infectious Diseases, Yale University, shared results of a phase 3 registrational trial of ibalizumab - a new class of antiretroviral agents for HIV that's a monoclonal antibody that targets the CD4 receptor. According to Emu, it's a completely new mechanism of action. This phase 3 trial specifically enrolled patients with multi-drug resistant HIV. The week 24 results showed ibalizumab's benefit in reducing viral load and an increase in cells that measure immunologic function in patients.

"I think this is really exciting, because over the three decades that we have been treating HIV, the importance of continuing to discover and develop new classes of drugs is critical -- patients do become resistant to drugs, even though we have a fabulous armamentarium of antiretrovirals right now," said Brindu. She believed this study focused on a very small percentage of the American population of the infected individuals who are highly treatment experienced. "Even though we have a lot of drugs, because of the resistance profile of their virus, they don't have a lot of options, so what these results mean for the most vulnerable of our patients is that they have access now to a new class of drugs," Emu concluded.

Related Videos
Age, Race, Ethnicity Disparities Hinder Celiac Disease Screening, with Debra Silberg, MD, PhD
Lauren Collen, MD: Advanced Combination Therapy May Be Effective Option for Pediatric Refractory IBD
Lauren Collen, MD: Some Fragrances May be More Prevalent in Exposomes of Children with Crohn’s Disease
Impact of Long Hospital Stays on Pediatric Gastroparesis Management with Christian Sadaka, MD
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Implications of Findings on Patient-Reported Outcomes for Roflumilast Foam, with Melinda Gooderham, MD
New Findings on Psoriasis Outcomes for Roflumilast Foam 0.3%, with Melinda Gooderham, MD
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.